(24/7 MARKET NEWS) – Biophytis SA (Nasdaq: BPTS) released the full results from its phase 2-3 COVA clinical study evaluating Sarconeos (BIO101) in the treatment of COVID-19-related respiratory failure, this morning.
Biophytis is trading at $0.6702, up 0.0802 (+13.59%), on volume of more than 1.6 million premarket shares.
Its premarket high this morning is $0.9242 and its 52-week range is $0.52 to $7.11, with the next key inflection points being $0.89 and $1.
View source version: https://www.accesswire.com/723707/Biophytis-Reports-Positive-Post-hoc-Analysis-of-The-Phase-2-3-COVA-Clinical-Study-Strongly-Supporting-Therapeutic-Potential-of-Sarconeos-BIO101-In-COVID-19.
24/7 MARKET NEWS, INC Disclaimer
24/7 MARKET NEWS (“24/7 MN”) is dedicated to covering various underreported segments of the stock markets. Our goal is to help you to better understand these markets, but 24/7 MN is neither an investment advisor nor a financial advisor, and no information provided here is to be interpreted as a suggestion to buy or sell stocks or other investment products. All opinions, news, research, analysis, prices or other information contained on 247marketnews.com, its press releases, or other services are provided for educational purposes only and do not constitute investment advice. You are solely responsible for the investment decisions you make.